Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.

Breitenstein, Stefanie; Roessig, Lothar; Sandner, Peter; Lewis, Kelly S

Breitenstein, Stefanie; Roessig, Lothar; Sandner, Peter; Lewis, Kelly S.

Affiliation

Breitenstein S; Bayer AG, Wuppertal, 42069, Germany. stefanie.breitenstein@bayer.com.
Roessig L; Bayer AG, Wuppertal, 42069, Germany.
Sandner P; Bayer AG, Wuppertal, 42069, Germany.
Lewis KS; Bayer AG, Wuppertal, 42069, Germany.

Handb Exp Pharmacol ; 243: 225-247, 2017.

Article in En | MEDLINE | ID: mdl-27900610

Subject(s)

Benzoates/therapeutic use; Heart Failure/drug therapy; Heterocyclic Compounds, 2-Ring/therapeutic use; Pyrazoles/therapeutic use; Pyrimidines/therapeutic use; Soluble Guanylyl Cyclase/metabolism; Cyclic GMP/metabolism; Heart Failure/metabolism; Heart Failure/physiopathology; Humans; Nitric Oxide/metabolism; Signal Transduction; Stroke Volume

Key words

Cardiovascular; Cinaciguat; Cyclic guanosine monophosphate (cGMP); Heart failure (HF); Nitric oxide (NO); Riociguat; Soluble guanylate cyclase (sGC); Vericiguat; sGC activator; sGC stimulator

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Benzoates / Soluble Guanylyl Cyclase / Heart Failure / Heterocyclic Compounds, 2-Ring Limits: Humans Language: En Journal: Handb Exp Pharmacol Year: 2017 Document type: Article Affiliation country: Germany Country of publication: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google